Navigation Links
Cato Research Presents at OMICS Group Conference, 3rd International Conference on Pharmaceutical Regulatory Affairs
Date:10/21/2013

Durham, NC (PRWEB) October 21, 2013

Cato Research regulatory expert William Lee, Ph.D., R.A.C., Vice President of Regulatory Affairs at Cato Research, will present in San Francisco, California at the OMICS Group Conference, 3rd International Conference on Pharmaceutical Regulatory Affairs.

Dr. Lee's presentation is titled: "Regulatory Roadmap for Initiating a Gene Therapy Drug into Clinical Trials in the United States."

Abstract of Presentation:
Exciting progress has been made in the development of gene therapy, and experimental research has brought forward novel treatment opportunities for viral vectors, DNA vectors, and gene-modified cell therapies. Clinical development of a gene therapy drug is challenging, requiring understanding of controlled manufacturing, relevant nonclinical pharmacology and safety studies, and clinical risk factors. For initiating clinical trials in the United States, regulatory requirements for investigational gene therapy drugs are more stringent than those with other investigational biologics (recombinant antibodies or recombinant proteins).

This talk will highlight these requirements, including the following:
(1) Submissions to regulatory authorities
(2) Manufacturing
(3) Nonclinical studies

Dr. William Lee received his B.A. from The Johns Hopkins University and his Ph.D. from Cornell University Graduate School of Medical Sciences. Dr. Lee has 20 years of research and industry experience. His focus is on gene therapy with retroviral vectors, adeno-associated viral vectors, and DNA vectors. He spent 9 years at the gene therapy start-up firm Viagene, Inc., followed by 2 years at Chiron. In 1999, he joined Cato Research, in Durham, North Carolina, where he is currently Vice President, Regulatory Affairs. His projects have included the design of Phase 1 and Phase 2 protocols for a gene therapy drug and interactions with the FDA and NIH/OBA. Currently, he manages projects involving regulatory strategy and submissions of investigational new drug applications and marketing applications for biologics and drugs.

For more information about this event, please visit: http://www.cato.com/events.shtml.

About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service, global contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness.

For more information, please contact:
Cato Research
Phone: 919-361-2286
http://www.cato.com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11247724.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Medical Waste Disposal Services Procurement Research Report Now Available from IBISWorld
2. Colleen’s Dream Foundation Gifts $10,000 to The University of Texas MD Anderson Cancer Center to Support Ovarian Cancer Research
3. Smartphones, GPS part of UH scientists smoking cessation research
4. Trauma Fixation Market Analysis and 2019 Forecasts in New Research Report at RnRMarketResearch.com
5. Lean On Life Supports New Research That Reveals Coconut Water’s Popularity
6. Orthopedic Market: Contract Manufacturing, Trauma Devices, Bracing & Supports 2016 Forecasts in New Research Reports at ReportsnReports.com
7. Skid row cancer study has implications for treatment today, Penn researcher says
8. Gallo Research Center announces new round of awards for $20m US Army-funded research program
9. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
10. Researchers launch first-ever phase II safety study of rectal microbicide to prevent HIV
11. CWRU researchers probe brain implant failure and countermeasure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... Levels of a protein in the blood associated with heart disease ... the journal Radiology. , Heart disease and brain disease exact a major burden on ... population. Damage to both organs often occurs at a subclinical stage, or before signs ...
(Date:12/7/2016)... Camarillo, CA (PRWEB) , ... December 07, 2016 ... ... manufacturing high performance connectors, is now promoting to the US market its advanced ... SPRINGTAC®, ODU LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... Queens, NY (PRWEB) , ... December 07, 2016 , ... ... to business owners and families throughout the Five Boroughs, is launching a charity drive ... League works to continue the traditions and spirit of marines and Navy FMF Corpsmen. ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016  "Blood Tests replace Surgical Biopsies. ... The Diagnostic, Monitoring and Screening Test opportunities ... is occurring using in vitro blood testing to ... impressive backing, has announced a single blood test ... faster than the market. New technology that definitively ...
(Date:12/6/2016)... , Dec. 6, 2016 The pen ... by 2021 from USD 1.65 billion in 2016, growing ... of 2016 to 2021. Over the years, the ... order to cater to the growing demand for safety ... to the development of safety pen needles with an ...
(Date:12/6/2016)... , Dec. 6, 2016  BTL Aesthetics ... proving that its BTL Vanquish ME device was ... energy delivery to the targeted tissue. The result: ... 53% higher, with BTL Vanquish ME versus BTL ... our physician network and their patients with the ...
Breaking Medicine Technology: